Heterogeneity of platelet alloantigens and alloantibodies: New insights into structure and function

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 3, 2006, Pages 244-253

  Socher, Ines ^a   Kroll, Hartmut ^b   Santoso, Sentot ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b German Red Cross Blood Transfusion Service NSTOB   (Germany)

Author keywords

Alloantigens, human platelet: structure, function; Thrombocytopenia, alloimmune

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; ALPHA2 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; VERY LATE ACTIVATION ANTIGEN 2;

ALLOIMMUNITY; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; BLEEDING; GENOTYPE; HUMAN; MICROARRAY ANALYSIS; POSTTRANSFUSION PURPURA; PURPURA; REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 33745463996     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092578     Document Type: Review

References (79)

1. Beiboer SH, Wieringa-Jelsma T, Maaskant-Van Wijk PA, van der Schoot CE, van Zwieten R, Roos D, den Dunnen JT, de Haas M: Rapid genotyping of blood group antigens by multiplex polymerase chain reaction and DNA microarray hybridization. Transfusion 2005;45:667-679.
2. Bugert P, McBride S, Smith G, Dugrillon A, Kluter H, Ouwehand WH, Metcalfe P: Microarray-based genotyping for blood groups: comparison of gene array and 5′-nuclease assay techniques with human platelet antigen as a model. Transfusion 2005;45:654-659.
3. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C: Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-1726.
4. McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods VL Jr: Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 1987;70:1040-1045.
5. Bussel JB, Zacharoulis S, Kramer K, McFarland JG, Pauliny J, Kaplan C: Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005;45:176-183.
6. Williamson LM, Hackett G, Rennie J, Palmer CR, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand WH: The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998;92:2280-2287.
7. Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S: 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;i:363-366.
8. Valentin N, Visentin GP, Newman PJ: Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 1995;85:3028-3033.
9. Metcalfe P, Watkins NA, Ouwehand WH, Kaplan C, Newman P, Kekomaki R, De Haas M, Aster R, Shibata Y, Smith J, Kiefel V, Santoso S: Nomenclature of human platelet antigens. Vox Sang 2003;85:240-245.
10. Santoso S, Kiefel V, Richter IG, Sachs UJ, Rahman A, Carl B, Kroll H: A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta (3) integrin: the Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002;99:1205-1214.
11. Kroll H, Yates J, Santoso S: Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005:45:353-358.
12. Birchall JE, Murphy MF, Kaplan C, Kroll H: European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003;122:275-288.
13. Kaplan C, Morel-Kopp MC, Kroll H, Kiefel V, Schlegel N, Chesnel N, Mueller-Eckhardt C: HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-429.
14. Glade-Bender J, McFarland JG, Kaplan C, Porcelijn L, Bussel JB: Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001;138:862-867.
15. Ertel K, Al-Tawil M, Santoso S, Kroll H: Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366-373.
16. Peterson JA, Balthazor SM, Curtis BR, McFarland JG, Aster RH: Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 2005;45:1487-1495.
17. Kaplan C, Porcelijn L, Vanlieferinghen P, Julien E, Bianchi F, Martageix C, Bertrand G, Jallu V: Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families. Transfusion 2005;45:1799-1803.
18. Ni H, Chen P, Spring CM, Sayeh E, Semple JW, Lazarus AH, Hynes RO, Freedman J: A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2005;107:2976-2983.
19. Kroll H, Kiefel V, Mueller-Eckhardt C: Die Post-transfusionelle Purpura. Klinische und immunologische Untersuchungen bei 38 Patientinnen. Infusionsther Transfusionsmed 1993;20:198-204.
20. Mueller-Eckhardt C: Post-transfusion purpura. Br J Haematol 1986;64:419-424.
21. Williamson L, Cohen H, Love E, Jones H, Todd A, Soldan K: The Serious Hazards of Transfusion (SHOT) initiative: the UK approach to haemovigilance. Vox Sang 2000;78(suppl 2):291-295.
22. Kiefel V, Konig C, Kroll H, Santoso S: Platelet alloantibodies in transfused patients. Transfusion 2001;41:766-770.
23. Novotny VM, van Doorn R, Witvliet MD, Claas FH, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995;85:1736-1741.
24. Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D: Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984-987.
25. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
26. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571.
27. DeSimone DW: Adhesion and matrix in vertebrate development. Curr Opin Cell Biol 1994;6:747-751.
28. Price DT, Loscalzo J: Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
29. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA: Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001;294:339-345.
30. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA: Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004;432:59-67.
31. Xiong JP, Stehle T, Goodman SL, Arnaout MA: A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem 2004;279:40252-40254.
32. Shattil SJ, Newman PJ: Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606-1615.
33. Takagi J, Petre BM, Walz T, Springer TA: Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002;110:599-511.
34. Xiong JP, Stehle T, Goodman SL, Arnaout MA: New insights into the structural basis of integrin activation. Blood 2003;102:1155-1159.
35. Santoso S, Kunicki T: Platelet receptor polymorphisms and thrombotic risk. Ital Heart J 2001;2:811-815.
36. Santoso S: Platelet polymorphisms in thrombotic disorders. Transfus Clin Biol 2001;8:261-266.
37. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094.
38. Bray PF: Integrin polymorphisms as risk factors for thrombosis. Thromb Haemost 1999;82:337-344.
39. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF: The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793-802.
40. Newman PJ, Martin LS, Knipp MA, Kahn RA: Studies on the nature of the human platelet alloantigen, PlA1: localization to a 17,000-dalton polypeptide. Mol Immunol 1985;22:719-729.
41. Flug F, Espinola R, Liu LX, SinQuee C, DaRosso R, Nardi M, Karpatkin S: A 13-mer peptide straddling the leucine33/proline33 polymorphism in glycoprotein IIIa does not define the PLA1 epitope. Blood 1991;77:1964-1969.
42. Bowditch RD, Tani PH, Halloran CE, Frelinger AL 3rd, McMillan R, Ginsberg MH: Localization of a PlA1 epitope to the amino terminal 66 residues of platelet glycoprotein IIIa. Blood 1992;79:559-562.
43. Barron-Casella EA, Kickler TS, Rogers OC, CaselIa JF: Expression and purification of functional recombinant epitopes for the platelet antigens, PlA1 and PlA2. Blood 1994;84:1157-1163.
44. Beer J, Coller BS: Evidence that platelet glycoprotein IIIa has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem 1989;264:17564-17573.
45. Kunicki TJ, Honda S, Dawson B, Honda Y, Ruan C, Aster RH: The P1A alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin beta 3 subunit. Blood Cells Mol Dis 1995;21:131-141.
46. Honda S, Honda Y, Bauer B, Ruan C, Kunicki TJ: The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin beta 3. Blood 1995;86:234-242.
47. Watkins NA, Schaffner-Reckinger E, Allen DL, Howkins GJ, Brons NH, Smith GA, Metcalfe P, Murphy MF, Kieffer N, Ouwehand WH: HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet beta 3 integrin that disrupts the HPA-1a epitope. Blood 2002;99:1833-1839.
48. Liu LX, Nardi MA, Casella JF, Karpatkin S: Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood 1996;88:3601-3607.
49. Santoso S, Kalb R, Walka M, Kiefel V, Mueller-Eckhardt C, Newman PJ: The human platelet alloantigens Br(a) and Brb are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit alpha 2). J Clin Invest 1993;92:2427-2432.
50. Goldberger A, Kolodziej M, Poncz M, Bennett JS, Newman PJ: Effect of single amino acid substitutions on the formation of the PlA and Bak alloantigenic epitopes. Blood 1991;78:681-687.
51. Take H, Tomiyama Y, Shibata Y, Furubayashi T, Honda S, Mizutani H, Nishiura T, Tsubakio T, Kurata Y, Yonezawa T, et al: Demonstration of the heterogeneity of epitopes of the platelet-specific alloantigen, Baka. Br J Haematol 1990;76:395-400.
52. Djaffar I, Vilette D, Pidard D, Wautier JL, Rosa JP: Human platelet antigen 3 (HPA-3): localization of the determinant of the alloantibody Lek(a) (HPA-3a) to the C-terminus of platelet glycoprotein IIb heavy chain and contribution of O-linked carbohydrates. Thromb Haemost 1993;69:485-489.
53. Calvete JJ, Muniz-Diaz E: Localization of an O-glycosylation site in the alpha-subunit of the human platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen expression. FEBS Lett 1993;328:30-34.
54. Niessner H, Clemetson KJ, Panzer S, Mueller-Eckhardt C, Santoso S, Bettelheim P: Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 1986;68:571-576.
55. Tholouli E, Hay CR, O'Gorman P, Makris M: Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004;127:209-213.
56. Deckmyn H, De Reys S: Functional effects of human antiplatelet antibodies. Semin Thromb Hemost 1995;21:46-59.
57. Deckmyn H, Vanhoorelbeke K, Peerlinck K: Inhibitory and activating human antiplatelet antibodies. Baillieres Clin Haematol 1998;11:343-359.
58. Nardi M, Tomlinson S, Greco MA, Karpatkin S: Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001;106:551-561.
59. Van Leeuwen EF, Leeksma OC, van Mourik JA, Engelfriet CP, von dem Borne AE: Effect of the binding of anti-Zwa antibodies on platelet function. Vox Sang 1984;47:280-289.
60. Duncan JR, Rosse WF: Alloantibody-induced platelet serotonin release is blocked by antibody to the platelet PLA1 antigen. Br J Haematol 1986;64:331-338.
61. Beadling WV, Herman JH, Stuart MJ, Keashen-Schnell M, Miller JL: Fetal bleeding in neonatal alloimmune thrombocytopenia mediated by antiPlAl is not associated with inhibition of fibrinogen binding to platelet GPIIb/IIIa. Am J Clin Pathol 1995;103:636-641.
62. Christie DJ, Leja DN, Carlson DL, Swinehart CD: Characterization of platelet activation induced by HLA antibodies associated with alloimmune thrombocytopenia. J Lab Clin Med 1993;121:437-443.
63. Christie DJ, Swinehart CD: Human platelet activating antibodies. Semin Thromb Hemost 1992;18:186-192.
64. Rubinstein E, Urso I, Boucheix C, Carroll RC: Platelet activation by cross-linking HLA class I molecules and Fc receptor. Blood 1992;79:2901-2908.
65. Kroll H, Penke G, Santoso S: Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)-1a. Thromb Haemost 2005;94:1224-1229.
66. Von dem Borne AE, Verheugt FW, Oosterhof F, von Riesz E, de la Riviere AB, Engelfriet CP: A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978;39:195-207.
67. Schneider W, Schnaidt M: The platelet adhesion immunofluorescence test: a modification of the platelet suspension immunofluorescence test. Blut 1981;43:389-392.
68. Kiefel V: The MAIPA assay and its applications in immunohaematology. Transfus Med 1992;2:181-188.
69. Metcalfe P, Allen D, Chapman J, Ouwehand WH: Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens. Br J Haematol 1997;97:204-207.
70. Menitove JE, Pereira J, Hoffman R, Anderson T, Fried W, Aster RH: Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 1989;73:1561-1569.
71. Carl B, Kroll H, Bux J, Bein G, Santoso S: B-lymphoblastoid cell lines as a source of reference DNA for human platelet and neutrophil antigen genotyping. Transfusion 2000;40:62-68.
72. Davoren A, Curtis BR, Aster RH, McFarland JG: Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004;44:1220-1225.
73. Morel-Kopp MC, Daviet L, McGregor J, Kaplan C: Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis 1996;7:144-146.
74. Fagerstam LG, Frostell A, Karlsson R, Kullman M, Larsson A, Malmqvist M, Butt H: Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. J Mol Recognit 1990;3:208-214.
75. Chaiken I, Rose S, Karlsson R: Analysis of macromolecular interactions using immobilized ligands. Anal Biochem 1992;201:197-210.
76. Malmqvist M: Biospecific interaction analysis using biosensor technology. Nature 1993;361:186-187.
77. Myszka DG: Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotecnnol 1997;8:50-57.
78. Kimura S, Yurugi K, Segawa H, Kuroda J, Sato K, Nogawa M, Yuasa T, Egawa H, Tanaka K, Maekawa T: Rapid quantitation of immunoglobulin G antibodies specific for blood group antigens A and B by surface plasmon resonance. Transfusion 2005;45:56-62.
79. Humphries MJ, Mould AP: Structure. An anthropomorphic integrin. Science 2001;294:316-317.